Introduction
Recently we have described a new series of potential antithrombotic compounds 1 based on a 2,4-dimethyl-3,4-dihydro-2H-benzo[b] [1, 4] oxazine scaffold possessing both thrombin inhibitory and fibrinogen receptor antagonistic activities. 1 In an attempt to study structure-activity relationships and improve both their thrombin inhibitory activity and fibrinogen receptor binding affinity, we systematically introduced fluorine into different positions of the P3 benzyl group and replaced the basic benzamidino group present in 1 with [1, 2, 4] triazolo [4,3-b] pyridazine-6-yl moiety that could mimic the benzamidino part of the molecule (Figure 1 ). It is well documented that aromatic carbon-bound fluorine can participate in hydrogen bonding and electrostatic interactions 2 thus contributing to the binding of drug molecules to their targets. 3 Since many potent thrombin inhibitors possessing a highly basic benzamidine moiety lack oral whereas replacement of the benzamidine functionality in 1 by [1, 2, 4] triazolo [4,3-b] pyridazine-6-yl group to obtain analogues 14-17, had a detrimental effect on thrombin inhibition and platelet fibrinogen receptor binding. On the contrary, the antiproliferative activity of compounds 1 studied on two endothelial (HMEC-1, BAEC) and two cancer (HELA, MCF-7) cell lines in connection with their antiangiogenic potential related to their thrombin inhibitory and fibrinogen receptor antagonistic activity, remained preserved in [1, 2, 4] triazolo [4,3-b] pyridazine compounds 14-17. 
Results and Discussion
The synthesis of target [1, 2, 4] triazolo [4,3-b] pyridazine compounds 14-17 is depicted in Scheme 3. The key intermediate 2-hydroxymethylbenzo[b] [1, 4] oxazine derivative 9 was prepared as described, from 2-amino-5-nitrophenol 6 in three steps via i) cyclization affording ethyl 2,4-dimethyl-7-nitro-3-oxo-3,4-dihydro-2H-benzo[b] [1, 4] oxazine-2-carboxylate 7, ii) its Nmethylation to 8 10 and iii) subsequent borane reduction 1b of 8 (Scheme 2). 6-Chloro- [1, 2, 4] triazolo [4,3-b] pyridazine 4 was also obtained by a literature procedure, involving cyclization of 3-chloro-6-hydrazinylpyridazine 3 with diethyl ethoxymethylenemalonate, 11 and cyclization of 3 with triethyl orthoacetate afforded 6-chloro-3-methyl- [1, 2, 4] triazolo [4,3-b] pyridazine 5 12 (Scheme 1). As depicted in Scheme 3, substitution of chlorine in [1, 2, 4] triazolo [4,3- After their reduction to amino derivatives 11a and 11b, N-benzylation at the aromatic amino group was carried out via imines formed with benzaldehyde, 4-fluorobenzaldehyde or 3,5-difluorobenzaldehyde, and their reduction using sodium borohydride to give compounds 12a-c and 13a-c. Acylation of amines 12 and 13 with ethyloxalyl chloride led to carboxamides 14a-c and 15a-c, respectively. Finally, hydrolysis of the ethyl esters with 1M lithium hydroxide gave the corresponding carboxylic acids 16a-c and 17a-c.
Compounds 14-17 were tested for thrombin inhibition according to a previously described protocol 1b and found to be devoid of thrombin inhibitory activity (Ki > 300 μM; results not shown) indicating that in this compound class substitution of the benzamidine with a [1, 2, 4] triazolo [4,3-b] pyridazin-6-yl moiety is detrimental for thrombin inhibition. Also the affinity for binding to platelet fibrinogen receptor tested according to a published procedure 1b was lost (IC50 > 100 μM; results not shown), indicating again that in this type of compound for preservation of fibrinogen receptor antagonistic activity the benzamidine moiety cannot be replaced by a [1, 2, 4] triazolo [4,3-b] pyridazine core. Table 1 indicate that esters 14a-c and 15a-c inhibit the proliferation of both endothelial (HMEC and BAEC) cell lines and both carcinoma (HELA and MCF-7) cell lines, with IC50 values ranging from 36.6 to 46.0 μM for HMEC-1, 33.5 to 38.0 μM for BAEC, 31.2 to 39.3 μM for HELA and 9.8 to 24.2 μM for MCF-7 cell lines, and were roughly 10-fold less potent than esters 1. 9 A combination of ionic structures (amidinium ion) with lipophilic parts very often gives rise to inhibition of cell growth, which may account for the higher activity of the amidine derivatives in cell proliferation assays. The carboxylic acids 16a-c and 17a-c were devoid of anti-proliferative activity, suggesting their insufficient cellular uptake. Compounds 14a-c and 15a-c were weakly active in cell migration assay 14 but proved to be inactive in tube formation assay 14 and chorioallantoic membrane (CAM) assay 15 (data not shown), whereas carboxylic acids 16a-c and 17a-c did not show any activity in these three assays. 
Conclusions
Compounds 14 -17 were synthesized as analogues of potential dual antithrombotic compounds 1 possessing thrombin inhibitory and fibrinogen receptor antagonistic activity. The replacement of the benzamidine functionality of compounds 1 with a [1,2,4]triazolo [4,3-b] pyridazine moiety resulted in loss of thrombin inhibitory and fibrinogen receptor antagonistic activity. However, anti-proliferative activity against HMEC-1, BAEC, HELA and MCF-7 cell lines inherent to benzamidines 1 was retained in esters 14a-c and 15a-c, indicating that this activity may not be attributed to the presence of a basic benzamidino group.
Experimental Section
General. Chemicals were obtained from Acros, Sigma-Aldrich, Fluka and Alfa Aesar and used without further purification. Hydrogenation reactions were carried out using a Parr 4842 hydrogenation apparatus. Analytical TLC was performed on silica gel Merck 60 F254 plates (0.25 mm), using visualization with ultraviolet light. Column chromatography was carried out on silica gel 60 (particle size 240-400 mesh). Melting points were determined on a Reichert hot stage microscope and are uncorrected. 1 H-NMR and 13 C-NMR spectra were recorded on a Bruker AVANCE III spectrometer (400 MHz for 1 H and 100 MHz for 13 C nuclei) in DMSO-d6 solution with TMS as the internal standard. The coupling constants (J) are given in Hz, and the splitting patterns are appointed as: s (singlet), d (doublet), dd (double doublet), t (triplet) and m (multiplet). IR spectra were recorded on a Perkin-Elmer 1600 FT-IR spectrometer. Microanalyses were performed at University of Ljubljana, Faculty of Chemistry and Chemical Technology on a Perkin-Elmer C, H, N analyzer 240 C. Mass spectra were obtained at Jožef Stefan Institute, Ljubljana, using a VG-Analytical Autospec Q mass spectrometer. HPLC analyses were performed on an Agilent Technologies HP 1100 instrument with G1365B UV-VIS detector (254 nm), using an Eclips Plus C18 column (4.6 × 150 mm) at flow rate 1 mL/min. The eluant was a mixture of 0.1 % TFA in water (A) and methanol (B). Gradient was 40% B to 80% B in 15 minutes. Purification of final compounds, if necessary, was performed by reverse phase column chromatography using a Flash Purification System ISOLERA TM with 0.1 % TFA in water and methanol as an eluent. Synthesis of compounds 7, 8 and 9
1b and [1,2,4]triazolo [4,3-b] pyridazine building blocks 4-6 [11] [12] [13] were performed according to published synthetic procedures.
General procedure for the synthesis of compounds (10a) and (10b)
Compound 9 (7.70 g, 32.3 mmol) was dissolved in 100 ml absolute DMF and 60% NaH (1.4 g, 58.1 mmol) was added. The mixture was stirred for 1 h at room temperature under argon atmosphere, whereupon 6-chloro- [ 
General procedure for reduction of compounds (10a) and (10b) by catalytic hydrogenation
The hydrogenation reaction was performed in a hydrogenator (25 bar, 1 h, 10% Pd/C). A mixture of compound 10a (9.0 g, 24.3 mmol) dissolved in 100 ml MeOH and 10% Pd/C (0.9 g) was stirred at room temperature till the reaction was completed (1 h). The catalyst was filtered off and the solvent was evaporated in vacuo to yield 8. General procedure for reductive amination (aldimine formation/reduction) of compounds (11a) and (11b) Benzaldehyde (2.4 g, 22.3 mmol), amine 11a (8 g, 24.6 mmol) and molecular sieves (0.3 nm) were mixed in 100 ml absolute methanol at room temperature under argon atmosphere. The mixture was stirred overnight until the aldimine formation was complete. The aldimine in methanol was carefully treated with solid NaBH4 (1.6 eq, 35.7 mmol, 1.3 g) and the reaction mixture was stirred for additional 2 h. The solvent was removed in vacuo and the crude product isolated by extraction with dichloromethane (DCM). The product was purified by column chromatography using DCM/MeOH 20:1 as eluent to afford 12a as yellow powder (5.2 g, yield 51%). 1,2,4]Triazolo[4,3-b]pyridazin-6-yloxy)methyl)-N-benzyl-2,4-dimethyl-3,4-dihydro-2H-1,4-benzoxazin-7-amine (12a) 2-(([1,2,4]Triazolo[4,3-b]pyridazin-6-yloxy)methyl)-N-(4-fluorobenzyl)-2,4-dimethyl-3,4-dihydro-2H-1,4-benzoxazin-7-amine (12b) N-(3,5-Difluorobenzyl)-2,4-dimethyl-2-(((3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)-methyl)-3,4-dihydro-2H-1,4-benzoxazin-7-amine (13c) 
2-(([

2-(([1,2,4]Triazolo[4,3-b]pyridazin-6-yloxy)methyl)-N-(3,5-difluorobenzyl)-2,4-dimethyl-3,4-dihydro-2H-1,4-benzoxazin-7-amine (12c
N-Benzyl-2,4-dimethyl-2-(((3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)methyl)-3,4-dihydro-2H-1,4-benzoxazin-7-amine (13a):
N-(4-Fluorobenzyl)-2,4-dimethyl-2-(((3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)oxy)-methyl)-3,4-dihydro-2H-1,4-benzoxazin-7-amine (13b
General procedure for preparation of N-acylated compounds (14a-c) and (15a-c)
Ethyloxalyl chloride (1.6 g, 11.5 mmol) was added to a solution of compound 12a (4.0 g, 9.6 mmol) and triethylamine (1.2 g, 11.5 mmol) in dichloromethane (70 ml) and the mixture stirred for 2 h. The solvent was removed under reduced pressure, the residue dissolved in ethyl acetate (50 ml) and washed successively with a 10% citric acid solution (3 x 50 ml), saturated NaHCO3 solution (3 x 50 ml) and brine (1 x 50 ml). The organic phase was dried over Na2SO4 and the solvent evaporated under reduced pressure. The oily product was purified by column chromatography using petroleum ether/ethyl acetate (1.5:1) as eluent to afford 14a as a white powder (2.9 g, yield 58%). 2-(([1,2,4]triazolo[4,3-b]pyridazin-6-yloxy)methyl)-2,4-dimethyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl) 2-(([1,2,4]triazolo[4,3-b]pyridazin-6-yloxy)methyl)-2,4-dimethyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)(4-fluorobenzyl)amino)-2-oxoacetate (14b) . White powder, yield 2.6 g (52%); mp 73-75 °C; 1 H NMR (400 MHz, DMSO-d6): δ 0.72 (t, J 7.1 Hz, 3H, CH2CH3), 1.32 (s, 3H, 2-CH3), 2. 78 (s, 3H, N-CH3), 3.01 (d, J 11.9 Hz, 1H, 3-H), 3.27 (d, overlapped with water,  1H, 3-H 2-(([1,2,4]triazolo[4,3-b]pyridazin-6-yloxy)methyl)-2,4-dimethyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)(3,5-difluorobenzyl) Ethyl 2-(benzyl(2,4-dimethyl-2-(((3-methyl-[1,2,4 
Ethyl 2-((
General procedure for alkaline hydrolysis of ethyl esters (14a-c) and (15a-c)
To the solution of ester 14a (1 g, 1.94 mmol) in tetrahydrofuran (6 mL) and methanol (2 ml), 1M LiOH (11.6 ml, 11.6 mmol) was added and the reaction mixture stirred at room temperature for 2 hours. Solvent was evaporated under vacuum and the resulting aqueous solution neutralized with 1M hydrochloric acid until the product started to precipitate. The product was filtered to obtain 16a as a pale purple powder (521 mg, yield 55%). 2-(([1,2,4]Triazolo[4,3-b]pyridazin-6-yloxy)methyl)-2,4-dimethyl-3,4-dihydro-2H-1,4 2-(([1,2,4]Triazolo[4,3-b]pyridazin-6-yloxy)methyl)-2,4-dimethyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)(4-fluorobenzyl)amino)-2-oxoacetic acid (16b) 
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